Therapeutic exploration of double-expressor diffuse large B-cell lymphoma in the era of new drugs
Double-expressor of MYC and BCL2 is an independent prognostic factor for diffuse large B-cell lymphoma,and double-expressor lymphoma responds poorly to the standard first-line treatment regimen R-CHOP,with a significant shortening of 5-year overall survival and progression free survival.How to improve the survival of patients with double-expressor lymphoma is one of the difficulties in the treatment of diffuse large B-cell lymphoma in clinical practice,and there is an urgent need for the development of novel targeting agents and innovative therapies.In the era of new drugs,the therapeutic exploration of double-expressor lymphoma has been deepening,and this article introduces new drug clinical trials and therapeutic explorations carried out for double-expressor lymphoma based on the types of new drugs.
double-expressordiffuse large B-cell lymphomanew drug therapyclinical trial
NETL
NSTL
万方数据
